Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients.

Arasaratnam RJ, Tzannou I, Gray T, Aguayo-Hiraldo PI, Kuvalekar M, Naik S, Gaikwad A, Liu H, Miloh T, Vera JF, Himes RW, Munoz FM, Leen AM.

Am J Transplant. 2018 Jun 13. doi: 10.1111/ajt.14967. [Epub ahead of print]

PMID:
29900673
2.

Enhancing the potency and specificity of engineered T cells for cancer treatment.

Sukumaran S, Watanabe N, Bajgain P, Raja K, Mohammed S, Fisher WE, Brenner MK, Leen AM, Vera JF.

Cancer Discov. 2018 Jun 7. pii: CD-17-1298. doi: 10.1158/2159-8290.CD-17-1298. [Epub ahead of print]

PMID:
29880586
3.

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.

Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM, Vera JF.

J Immunother Cancer. 2018 May 10;6(1):34. doi: 10.1186/s40425-018-0347-5.

4.

Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy.

Tzannou I, Nicholas SK, Lulla P, Aguayo-Hiraldo PI, Misra A, Martinez CA, Machado AA, Orange JS, Piedra PA, Vera JF, Leen AM.

J Infect Dis. 2017 Sep 15;216(6):678-687. doi: 10.1093/infdis/jix358.

PMID:
28934427
5.

Characterizing the Cellular Immune Response to Parainfluenza Virus 3.

Aguayo-Hiraldo PI, Arasaratnam RJ, Tzannou I, Kuvalekar M, Lulla P, Naik S, Martinez CA, Piedra PA, Vera JF, Leen AM.

J Infect Dis. 2017 Jul 15;216(2):153-161. doi: 10.1093/infdis/jix203.

PMID:
28472480
6.

Variance-Based Cluster Selection Criteria in a K-Means Framework for One-Mode Dissimilarity Data.

Vera JF, Macías R.

Psychometrika. 2017 Jun;82(2):275-294. doi: 10.1007/s11336-017-9561-1. Epub 2017 Feb 13.

PMID:
28194550
7.

Fine-tuning the CAR spacer improves T-cell potency.

Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.

8.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF.

Mol Ther. 2017 Jan 4;25(1):249-258. doi: 10.1016/j.ymthe.2016.10.016. Epub 2017 Jan 4.

9.

Distance stability analysis in multidimensional scaling using the jackknife method.

Vera JF.

Br J Math Stat Psychol. 2017 Feb;70(1):25-41. doi: 10.1111/bmsp.12079. Epub 2016 Dec 20.

PMID:
27996084
10.

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.

Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM.

J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.

11.

Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.

Mata M, Vera JF, Gerken C, Rooney CM, Miller T, Pfent C, Wang LL, Wilson-Robles HM, Gottschalk S.

J Immunother. 2014 Oct;37(8):407-15. doi: 10.1097/CJI.0000000000000052.

12.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Papadopoulou A, Gerdemann U, Katari UL, Tzannou I, Liu H, Martinez C, Leung K, Carrum G, Gee AP, Vera JF, Krance RA, Brenner MK, Rooney CM, Heslop HE, Leen AM.

Sci Transl Med. 2014 Jun 25;6(242):242ra83. doi: 10.1126/scitranslmed.3008825.

13.

Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK, Vera JF.

Mol Ther. 2014 Jun;22(6):1211-1220. doi: 10.1038/mt.2014.47. Epub 2014 Mar 20.

14.

Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.

Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM.

J Immunother. 2014 May;37(4):193-203. doi: 10.1097/CJI.0000000000000014.

15.

A latent class distance association model for cross-classified data with a categorical response variable.

Vera JF, de Rooij M, Heiser WJ.

Br J Math Stat Psychol. 2014 Nov;67(3):514-40. doi: 10.1111/bmsp.12038. Epub 2014 Mar 24.

PMID:
24661132
16.

Optimizing the production of suspension cells using the G-Rex "M" series.

Bajgain P, Mucharla R, Wilson J, Welch D, Anurathapan U, Liang B, Lu X, Ripple K, Centanni JM, Hall C, Hsu D, Couture LA, Gupta S, Gee AP, Heslop HE, Leen AM, Rooney CM, Vera JF.

Mol Ther Methods Clin Dev. 2014 May 14;1:14015. doi: 10.1038/mtm.2014.15. eCollection 2014.

17.

T lymphocytes targeting native receptors.

Rooney CM, Leen AM, Vera JF, Heslop HE.

Immunol Rev. 2014 Jan;257(1):39-55. doi: 10.1111/imr.12133. Review.

18.

Engineered T cells for cancer treatment.

Anurathapan U, Leen AM, Brenner MK, Vera JF.

Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13. Review.

19.

Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Mol Ther. 2014 Mar;22(3):623-633. doi: 10.1038/mt.2013.262. Epub 2013 Nov 28.

20.

Is cancer gene therapy an empty suit?

Brenner MK, Gottschalk S, Leen AM, Vera JF.

Lancet Oncol. 2013 Oct;14(11):e447-e456. doi: 10.1016/S1470-2045(13)70173-6. Review.

21.

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, Rooney CM, Leen AM, Brenner MK, Vera JF.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):123-31, S1. doi: 10.1038/pcan.2012.49. Epub 2013 Jan 8.

22.

Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.

Chakraborty R, Mahendravada A, Perna SK, Rooney CM, Heslop HE, Vera JF, Savoldo B, Dotti G.

Haematologica. 2013 Apr;98(4):533-7. doi: 10.3324/haematol.2012.076430. Epub 2012 Dec 14.

23.
24.

Optimization manufacture of virus- and tumor-specific T cells.

Lapteva N, Vera JF.

Stem Cells Int. 2011;2011:434392. doi: 10.4061/2011/434392. Epub 2011 Sep 11.

25.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, Brenner MK, Bollard CM, Rooney CM, Leen AM.

Mol Ther. 2011 Dec;19(12):2258-68. doi: 10.1038/mt.2011.167. Epub 2011 Sep 13.

26.

Engineered T cells for pancreatic cancer treatment.

Katari UL, Keirnan JM, Worth AC, Hodges SE, Leen AM, Fisher WE, Vera JF.

HPB (Oxford). 2011 Sep;13(9):643-50. doi: 10.1111/j.1477-2574.2011.00344.x. Epub 2011 Jul 20.

27.

Treatment of Kleine-Levin syndrome with sodium oxybate.

Ortega-Albás JJ, Díaz JR, López-Bernabé R, Vera JF, Alós M, Serrano AL.

Sleep Med. 2011 Aug;12(7):730. doi: 10.1016/j.sleep.2011.06.001. Epub 2011 Jul 16. No abstract available.

PMID:
21763197
28.

Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Gerdemann U, Vera JF, Rooney CM, Leen AM.

J Vis Exp. 2011 May 27;(51). pii: 2736. doi: 10.3791/2736.

29.

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, Wilson J, Dotti G, Heslop HE, Leen AM, Rooney CM.

J Immunother. 2010 Apr;33(3):305-15. doi: 10.1097/CJI.0b013e3181c0c3cb.

30.

Immunotherapy of human cancers using gene modified T lymphocytes.

Vera JF, Brenner MK, Dotti G.

Curr Gene Ther. 2009 Oct;9(5):396-408. Review.

31.

Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, June CH, Rooney CM, Wilson MH.

J Immunother. 2009 Oct;32(8):826-36. doi: 10.1097/CJI.0b013e3181ad762b.

32.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Gerdemann U, Christin AS, Vera JF, Ramos CA, Fujita Y, Liu H, Dilloo D, Heslop HE, Brenner MK, Rooney CM, Leen AM.

Mol Ther. 2009 Sep;17(9):1616-25. doi: 10.1038/mt.2009.140. Epub 2009 Jul 7.

33.

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Mol Ther. 2009 May;17(5):880-8. doi: 10.1038/mt.2009.34. Epub 2009 Mar 3.

34.

[Frontal absences and 'pseudo-absences'].

Ortega-Albás JJ, Serrano AL, López-Bernabé R, Cerveró-Albert D, Vera JF.

Rev Neurol. 2008 Feb 16-29;46(4):256; author reply 256. Spanish. No abstract available.

35.

Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas.

Tabernero MD, Espinosa AB, Maillo A, Rebelo O, Vera JF, Sayagues JM, Merino M, Diaz P, Sousa P, Orfao A.

Oncologist. 2007 Oct;12(10):1225-36.

36.

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, Heslop HE, Rooney CM, Brenner MK, Dotti G.

Blood. 2007 Oct 15;110(8):2793-802. Epub 2007 Jul 17.

37.

CARGO: a web portal to integrate customized biological information.

Cases I, Pisano DG, Andres E, Carro A, Fernández JM, Gómez-López G, Rodriguez JM, Vera JF, Valencia A, Rojas AM.

Nucleic Acids Res. 2007 Jul;35(Web Server issue):W16-20. Epub 2007 May 5.

38.

Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression.

Sayagués JM, Tabernero MD, Maíllo A, Trelles O, Espinosa AB, Sarasquete ME, Merino M, Rasillo A, Vera JF, Santos-Briz A, de Alava E, Garcia-Macias MC, Orfao A.

J Neuropathol Exp Neurol. 2006 May;65(5):445-54.

PMID:
16772868
39.

Sucrose permeability in children with gastric damage and Helicobacter pylori infection.

Vera JF, Gotteland M, Chavez E, Vial MT, Kakarieka E, Brunser O.

J Pediatr Gastroenterol Nutr. 1997 May;24(5):506-11.

PMID:
9161942

Supplemental Content

Support Center